TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37167303

Group type: EXPERIMENTAL
Intervention: Circulating miRNAs profiles according to the coronary pattern of the vascular compartment affectation.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Acetylcholine test for patients with isolated microvascular affectation or normal indexes.
Number of subjects: 100
Study: 37167616

Group type: EXPERIMENTAL
Intervention: Train the Brain programme (motor/cognitive intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-trained MCI controls
Number of subjects: 0
Study: 37167764

Group type: EXPERIMENTAL
Intervention: Nivolumab plus relatlimab (NIVO + RELA; 480 mg and 160 mg, respectively)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nivolumab (NIVO; 480 mg)
Number of subjects: 0
Study: 37167775

Group type: EXPERIMENTAL
Intervention: MACE (Major Adverse Cardiovascular Events)
Number of subjects: 49479

Group type: EXPERIMENTAL
Intervention: MACE
Number of subjects: 49479
Study: 37167996

Group type: EXPERIMENTAL
Intervention: Dolutegravir, emtricitabine, and tenofovir alafenamide
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Dolutegravir, emtricitabine, and tenofovir disoproxil fumarate
Number of subjects: 643

Group type: COMPARATOR
Intervention: Efavirenz, emtricitabine, and tenofovir disoproxil fumarate
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Combined dolutegravir groups
Number of subjects: 643

Group type: COMPARATOR
Intervention: Efavirenz-containing group
Number of subjects: 643
Study: 37168386

Group type: EXPERIMENTAL
Intervention: Decision aid for organized cancer screening
Number of subjects: 75000

Group type: COMPARATOR
Intervention: Standard organized cancer screening
Number of subjects: 75000
Study: 37168472

Group type: EXPERIMENTAL
Intervention: Rectal swabs and molecular diagnostic tests for detection of enteropathogens
Number of subjects: 0
Study: 37168686

Group type: EXPERIMENTAL
Intervention: Central blood pressure target (< 130 mm Hg)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Brachial blood pressure target (< 130 mm Hg)
Number of subjects: 116
Study: 37169219

Group type: EXPERIMENTAL
Intervention: Text messaging about diabetes prevention
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Prediabetes decision aid
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Both text messaging and prediabetes decision aid
Number of subjects: 656

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 656
Study: 37169336

Group type: EXPERIMENTAL
Intervention: Initial laparotomy
Number of subjects: 382

Group type: COMPARATOR
Intervention: Peritoneal drain
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Randomized infants
Number of subjects: 382

Group type: COMPARATOR
Intervention: Target population
Number of subjects: 382
Study: 37169401

Group type: EXPERIMENTAL
Intervention: CPAP treatment for 4 weeks
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: CPAP treatment for 24 months
Number of subjects: 130
Study: 37169489

Group type: EXPERIMENTAL
Intervention: Quincke needle
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Tuohy needle
Number of subjects: 230

Group type: COMPARATOR
Intervention: Overall incidence
Number of subjects: 230

Group type: COMPARATOR
Intervention: Bony contact during procedure
Number of subjects: 230
Study: 37169498

Group type: EXPERIMENTAL
Intervention: Procalcitonin point-of-care testing
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lung ultrasonography
Number of subjects: 12
Study: 37169499

Group type: EXPERIMENTAL
Intervention: Routine treatments for MG
Number of subjects: 1693

Group type: EXPERIMENTAL
Intervention: Side effects from treatments
Number of subjects: 1693

Group type: EXPERIMENTAL
Intervention: Comorbidities
Number of subjects: 1693

Group type: EXPERIMENTAL
Intervention: Hospital Anxiety and Depression Scale
Number of subjects: 1693

Group type: EXPERIMENTAL
Intervention: Work or study impact
Number of subjects: 1693
Study: 37169504

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) intervention, 3 sessions per week for 12 weeks on an ergometer bicycle.
Number of subjects: 80

Group type: COMPARATOR
Intervention: No exercise control group (part of the 1:1 allocation).
Number of subjects: 80
Study: 37169579

Group type: EXPERIMENTAL
Intervention: Hyper high haemoglobin content in red blood cells (Hyper-He) >49 pg
Number of subjects: 62
Study: 37169708

Group type: EXPERIMENTAL
Intervention: Emotion Focused Mindfulness Therapy (EFMT) group delivered by Zoom
Number of subjects: 48

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 48
Study: 37169780

Group type: EXPERIMENTAL
Intervention: Brain serotonin 4 receptor binding
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 0
Study: 37169835

Group type: EXPERIMENTAL
Intervention: Rituximab with IVIG
Number of subjects: 46

Group type: COMPARATOR
Intervention: Rituximab
Number of subjects: 46
Study: 37169992

Group type: EXPERIMENTAL
Intervention: Lipidomic measures (904 lipid species and 252 fatty acids)
Number of subjects: 706
Study: 37170018

Group type: EXPERIMENTAL
Intervention: Routine Discharge Plan (RDP)
Number of subjects: 802

Group type: COMPARATOR
Intervention: On-Demand Discharge Planning (DDP)
Number of subjects: 802
Study: 37170043

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Subcutaneous opioids
Number of subjects: 21
Study: 37170057

Group type: EXPERIMENTAL
Intervention: TMB-001 0.05%
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: TMB-001 0.1%
Number of subjects: 33

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 33
Study: 37170109

Group type: EXPERIMENTAL
Intervention: Mifepristone (1200 mg/day)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study: 37170123

Group type: EXPERIMENTAL
Intervention: Open abdomen (OA) management with negative peritoneal pressure therapy (NPPT) dressing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Formal closure of the fascia
Number of subjects: 0
Study: 37170159

Group type: EXPERIMENTAL
Intervention: Programmed flexor-extensor alternating electrical acupoint stimulation (PES)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional flexor-extensor alternating electrical acupoint stimulation (CES)
Number of subjects: 0
Study: 37170191

Group type: EXPERIMENTAL
Intervention: High-dose polyethylene glycol 3350 (PEG, 459 g) and Gatorade (1.5 times the standard-dose)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: High-dose polyethylene glycol 3350 (PEG, 612 g) and Gatorade (2.0 times the standard-dose)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard doses of PEG (306 g to 357 g) and Gatorade
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: High-dose preparations
Number of subjects: 69
Study: 37170232

Group type: EXPERIMENTAL
Intervention: Machine learning-enhanced echocardiography using 59 echocardiographic features in a gradient-boosting classifier.
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: Machine learning-enhanced echocardiography.
Number of subjects: 818
Study: 37170260

Group type: EXPERIMENTAL
Intervention: High concentration sodium bicarbonate dentifrice
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control dentifrice
Number of subjects: 20
Study: 37170284

Group type: EXPERIMENTAL
Intervention: Envarsus®
Number of subjects: 268

Group type: COMPARATOR
Intervention: Advagraf™
Number of subjects: 268
Study: 37170307

Group type: EXPERIMENTAL
Intervention: Adjuvant intravesical instillations of the drug selected based on drug screens in patient derived organoids (PDO) - Epirubicin, Mitomycin C, Gemcitabine, or Docetaxel for 6 instillations once weekly.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 37170329

Group type: EXPERIMENTAL
Intervention: Health-system-embedded deprescribing intervention (educational brochure and self-care handouts, decision support for providers)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Usual care clinics
Number of subjects: 18
Study: 37170385

Group type: EXPERIMENTAL
Intervention: Heart rate-controlled walking training 5 times a week for 45 minutes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual standard of care (control group)
Number of subjects: 0
Study: 37170480

Group type: EXPERIMENTAL
Intervention: mCIMT with real rTMS
Number of subjects: 46

Group type: COMPARATOR
Intervention: mCIMT with sham rTMS
Number of subjects: 46
Study: 37170709

Group type: EXPERIMENTAL
Intervention: 50 μg IFS
Number of subjects: 40

Group type: COMPARATOR
Intervention: 5 mg OM
Number of subjects: 40
Study: 37170711

Group type: EXPERIMENTAL
Intervention: SGLT2i
Number of subjects: 1700
Study: 37170806

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control
Number of subjects: 7678

Group type: COMPARATOR
Intervention: Standard blood pressure control
Number of subjects: 7678
Study: 37170812

Group type: EXPERIMENTAL
Intervention: Electrophysiological studies (EPS) with programmed ventricular stimulation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Repeat EPS after PVR
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Follow-up after PVR
Number of subjects: 120
Study: 37170814

Group type: EXPERIMENTAL
Intervention: High sFlt-1/PlGF Ratio
Number of subjects: 0
Study: 37170833

Group type: EXPERIMENTAL
Intervention: Lowest MEEi tertile (MEEi<0.031 mL/s/g)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Merged second and third tertiles (MEEi≥0.031)
Number of subjects: 78
Study: 37170950

Group type: EXPERIMENTAL
Intervention: 9-month structured, individualized and supervised exercise intervention
Number of subjects: 1
Study: 37171081

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral oxytocin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (medium pressure touch)
Number of subjects: 0
Study: 37171121

Group type: EXPERIMENTAL
Intervention: HEK293T generated AAV vectors (serotype 8, 9, and rh.10)
Number of subjects: 0
Study: 37171122

Group type: EXPERIMENTAL
Intervention: Videolaryngoscopy
Number of subjects: 759
Study: 37171199

Group type: EXPERIMENTAL
Intervention: SGLT2 inhibition for 2 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SGLT2 inhibition for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37171467

Group type: EXPERIMENTAL
Intervention: CamAPS FX hybrid closed loop (CL) system
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sensor-augmented pump (SAP)
Number of subjects: 35
Study: 37171597

Group type: EXPERIMENTAL
Intervention: Tafasitamab+lenalidomide
Number of subjects: 3454
Study: 37171602

Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted minimally invasive lamellar keratoplasty (FL-MILK)
Number of subjects: 56
Study: 37171620

Group type: EXPERIMENTAL
Intervention: Rituximab, bendamustine, and low-dose cytarabine (R-BAC)
Number of subjects: 57
Study: 37171634

Group type: EXPERIMENTAL
Intervention: Radioactive iodine therapy (RAI)
Number of subjects: 21
Study: 37171721

Group type: EXPERIMENTAL
Intervention: Talazoparib (oral, 1 mg once daily)
Number of subjects: 15
Study: 37171752

Group type: EXPERIMENTAL
Intervention: Apremilast
Number of subjects: 180
Study: 37171819

Group type: EXPERIMENTAL
Intervention: Engagement-focused care coordination (EFCC)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Problem-solving education (PSE)
Number of subjects: 230
Study: 37171851

Group type: EXPERIMENTAL
Intervention: Implementation intervention including real-time and web-based training, tobacco smoking treatment protocol, expert consultation, coaching, and organizational strategy meetings.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Implementation intervention
Number of subjects: 50
Study: 37171856

Group type: EXPERIMENTAL
Intervention: EHR notification
Number of subjects: 2877

Group type: COMPARATOR
Intervention: EHR notification (more than 5 notifications)
Number of subjects: 2877

Group type: EXPERIMENTAL
Intervention: Provider survey
Number of subjects: 2877
Study: 37171869

Group type: EXPERIMENTAL
Intervention: FT-EMDR
Number of subjects: 90

Group type: COMPARATOR
Intervention: S-EMDR
Number of subjects: 90
Study: 37171965

Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate (amox/clav) administered for 10 days
Number of subjects: 796

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 796

Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate (amox/clav) administered for 5 days
Number of subjects: 796
Study: 37171989

Group type: EXPERIMENTAL
Intervention: Neostigmine
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Spontaneous recovery
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cost analysis
Number of subjects: 200
Study: 37171994

Group type: EXPERIMENTAL
Intervention: Negative pressure application via Multi-Pressure Dial (MPD) system
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control (fellow eye)
Number of subjects: 58
Study: 37172100

Group type: EXPERIMENTAL
Intervention: IMA101 treatment (T-cell infusion and low-dose IL2)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Atezolizumab (Cohort 2)
Number of subjects: 14
Study: 37172109

Group type: EXPERIMENTAL
Intervention: Reduction and cast immobilization
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 438
Study: 37172116

Group type: EXPERIMENTAL
Intervention: Intensive treatment (SBP target, 110 to <130 mmHg)
Number of subjects: 8511

Group type: COMPARATOR
Intervention: Standard treatment (SBP target, 130 to <150 mmHg)
Number of subjects: 8511
Study: 37172125

Group type: COMPARATOR
Intervention: Telehealth group
Number of subjects: 66

Group type: COMPARATOR
Intervention: Hybrid group
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: In-person group
Number of subjects: 66
Study: 37172200

Group type: EXPERIMENTAL
Intervention: Quadrivalent meningococcal conjugate vaccine (one dose)
Number of subjects: 102
Study: 37172204

Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy (CIT)
Number of subjects: 926

Group type: EXPERIMENTAL
Intervention: Venetoclax-based therapies
Number of subjects: 926

Group type: COMPARATOR
Intervention: CIT
Number of subjects: 926

Group type: COMPARATOR
Intervention: Venetoclax-based treatments
Number of subjects: 926
Study: 37172214

Group type: EXPERIMENTAL
Intervention: Simulated residual OCT-μQFR
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Actual post-PCI OCT-μQFR
Number of subjects: 74
Study: 37172783

Group type: EXPERIMENTAL
Intervention: Various types of drug delivery systems (including anti-VEGF drugs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Innovative drug delivery systems
Number of subjects: 0
Study: 37172782

Group type: EXPERIMENTAL
Intervention: Novel treatments for uveitis (specific interventions not detailed in the abstract)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Current treatments involving immunosuppressive and anti-inflammatory medications
Number of subjects: 0
Study: 37172884

Group type: EXPERIMENTAL
Intervention: AAV8-hCARp.hCNGB3
Number of subjects: 23
Study: 37172934

Group type: EXPERIMENTAL
Intervention: 5 W power with automatic fiber traction speed of 0.7 mm/s (LEED, 71.4 J/cm)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: 7 W power with automatic fiber traction speed of 1.0 mm/s (LEED, 70 J/cm)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: 10 W power with automatic fiber traction speed of 1.5 mm/s (LEED, 66.7 J/cm)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Pain intensity along the target vein
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Necessity for analgesics
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Occurrence of significant complications
Number of subjects: 203
Study: 37172938

Group type: EXPERIMENTAL
Intervention: 3-second rule for high confidence assignment
Number of subjects: 1793

Group type: COMPARATOR
Intervention: Standard real-time optical diagnosis
Number of subjects: 1793
Study: 37172969

Group type: EXPERIMENTAL
Intervention: Neoadjuvant intratumoral influenza vaccine treatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 10
Study: 37173074

Group type: EXPERIMENTAL
Intervention: Chronic cough (CC)
Number of subjects: 1183

Group type: EXPERIMENTAL
Intervention: CT imaging parameters (total airway count, airway wall thickness, emphysema)
Number of subjects: 1183

Group type: EXPERIMENTAL
Intervention: CT parameters and CC
Number of subjects: 1183
Study: 37173099

Group type: EXPERIMENTAL
Intervention: Machine-learning-based risk score for net adverse clinical events (NACE) developed using random survival forest (RSF) and Cox regression models.
Number of subjects: 2215

Group type: EXPERIMENTAL
Intervention: Integer-based risk score for NACE.
Number of subjects: 2215

Group type: EXPERIMENTAL
Intervention: Decision curve analysis of the risk score.
Number of subjects: 2215
Study: 37173113

Group type: EXPERIMENTAL
Intervention: Environmental enrichment (EE) intervention consisting of six 40-min sessions over 9 days, including mindfulness in multisensory VR and indoor cycling with cognitive training.
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group receiving standard management for AUD.
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Environmental enrichment (EE) intervention.
Number of subjects: 135
Study: 37173116

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg once daily for 7 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: No additional postprocedural anticoagulation
Number of subjects: 0
Study: 37173129

Group type: EXPERIMENTAL
Intervention: Natalizumab treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interferon beta
Number of subjects: 0
Study: 37173224

Group type: EXPERIMENTAL
Intervention: Bispecific antibodies and other emerging treatment strategies
Number of subjects: 0
Study: 37173291

Group type: EXPERIMENTAL
Intervention: Computerized vestibular retraining therapy; 12 twice-weekly sessions.
Number of subjects: 13
Study: 37173355

Group type: EXPERIMENTAL
Intervention: St. George's Respiratory Questionnaire (SGRQ)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Euroquol-5D-5L (EQ-5D-5L)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Short form 36 (SF-36)
Number of subjects: 112
Study: 37173365

Group type: EXPERIMENTAL
Intervention: OBI-3424 administered intravenously at doses of 1, 2, 4, 6, 8, or 12 mg/m
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OBI-3424 at 12 mg/m
Number of subjects: 0
Study: 37173512

Group type: EXPERIMENTAL
Intervention: Intranasal esketamine treatment during induction phase (twice-weekly)
Number of subjects: 1148

Group type: EXPERIMENTAL
Intervention: Intranasal esketamine treatment during optimization/maintenance phase (individualized dosing)
Number of subjects: 1148

Group type: EXPERIMENTAL
Intervention: Long-term treatment with esketamine (up to 4.5 years)
Number of subjects: 1148
Study: 37173568

Group type: EXPERIMENTAL
Intervention: Active Shiatsu treatment
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham Shiatsu treatment
Number of subjects: 120
Study: 37173690

Group type: EXPERIMENTAL
Intervention: Polish version of the Alberta Infant Motor Scale (AIMS)
Number of subjects: 431
Study: 37173701

Group type: EXPERIMENTAL
Intervention: Male participants
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Female participants
Number of subjects: 200

Group type: COMPARATOR
Intervention: Both sexes
Number of subjects: 200
Study: 37173715

Group type: EXPERIMENTAL
Intervention: Subclavian vein catheterisation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Internal jugular vein catheterisation
Number of subjects: 100
Study: 37173764

Group type: EXPERIMENTAL
Intervention: Synchronous online delivered exercise maintenance classes with health coaching calls
Number of subjects: 40

Group type: COMPARATOR
Intervention: Synchronous online delivered exercise maintenance classes without health coaching calls
Number of subjects: 40
Study: 37173784

Group type: EXPERIMENTAL
Intervention: Citicoline 10 mg/kg/12h IV for 4 weeks plus supportive measures
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo plus supportive measures
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Citicoline treatment
Number of subjects: 80
Study: 37173791

Group type: EXPERIMENTAL
Intervention: CT1812
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study: 37173792

Group type: EXPERIMENTAL
Intervention: Behavioral Activation Treatment for Cardiac Smokers (BAT-CS)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Control (smoking cessation and general health education)
Number of subjects: 324
Study: 37173799

Group type: EXPERIMENTAL
Intervention: Smoke-Free Home SafeCare (SFH-SC)
Number of subjects: 8
Study: 37173865

Group type: EXPERIMENTAL
Intervention: Meaning-Centered Pain Coping Skills Training (MCPC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study: 37174154

Group type: EXPERIMENTAL
Intervention: Radon app for smartphones
Number of subjects: 116

Group type: COMPARATOR
Intervention: Printed brochures
Number of subjects: 116
Study: 37174643

Group type: EXPERIMENTAL
Intervention: Cladribine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (platform immunotherapy)
Number of subjects: 90
Study: 37174650

Group type: EXPERIMENTAL
Intervention: Probiotic formula containing three bifidobacteria; details on dosage and duration not provided.
Number of subjects: 0
Study: 37174706

Group type: EXPERIMENTAL
Intervention: CTLA-4 immune checkpoint inhibition (tremelimumab) combined with radiotherapy (RT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiotherapy (RT) with CTLA-4 immune checkpoint inhibition (ICI)
Number of subjects: 0
Study: 37174730

Group type: EXPERIMENTAL
Intervention: Vitamin C (Vit C)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Vitamin E (Vit E)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Melatonin (MT)
Number of subjects: 131

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 131
Study: 37174733

Group type: EXPERIMENTAL
Intervention: Spot urine proteinuria measurement
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Spot urine albuminuria measurement
Number of subjects: 47
Study: 37174969

Group type: EXPERIMENTAL
Intervention: Ultrasound examination of the larynx and trachea
Number of subjects: 300
Study: 37175874

Group type: EXPERIMENTAL
Intervention: Ipilimumab (10 mg/kg intravenously every 3 weeks × two doses)
Number of subjects: 0
Study: 37178136

Group type: EXPERIMENTAL
Intervention: Extended ablation group (clinical arrhythmia plus substrate-based ablation)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Limited ablation group (clinical arrhythmia ablation only)
Number of subjects: 77